319 related articles for article (PubMed ID: 26771747)
1. Epoch Analysis of On-Treatment Disability Progression Events over Time in the Tysabri Observational Program (TOP).
Wiendl H; Butzkueven H; Kappos L; Trojano M; Pellegrini F; Paes D; Zhang A; Belachew S;
PLoS One; 2016; 11(1):e0144834. PubMed ID: 26771747
[TBL] [Abstract][Full Text] [Related]
2. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.
Trojano M; Butzkueven H; Kappos L; Wiendl H; Spelman T; Pellegrini F; Chen Y; Dong Q; Koendgen H; Belachew S;
Mult Scler Relat Disord; 2018 Aug; 24():11-19. PubMed ID: 29860197
[TBL] [Abstract][Full Text] [Related]
3. Greater sensitivity to multiple sclerosis disability worsening and progression events using a roving versus a fixed reference value in a prospective cohort study.
Kappos L; Butzkueven H; Wiendl H; Spelman T; Pellegrini F; Chen Y; Dong Q; Koendgen H; Belachew S; Trojano M;
Mult Scler; 2018 Jun; 24(7):963-973. PubMed ID: 28554238
[TBL] [Abstract][Full Text] [Related]
4. Long-term disease activity and disability progression in relapsing-remitting multiple sclerosis patients on natalizumab.
Dekker I; Leurs CE; Hagens MHJ; van Kempen ZLE; Kleerekooper I; Lissenberg-Witte BI; Barkhof F; Uitdehaag BMJ; Balk LJ; Wattjes MP; Killestein J
Mult Scler Relat Disord; 2019 Aug; 33():82-87. PubMed ID: 31174043
[TBL] [Abstract][Full Text] [Related]
5. Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP).
Butzkueven H; Kappos L; Wiendl H; Trojano M; Spelman T; Chang I; Kasliwal R; Jaitly S; Campbell N; Ho PR; Licata S;
J Neurol Neurosurg Psychiatry; 2020 Jun; 91(6):660-668. PubMed ID: 32234967
[TBL] [Abstract][Full Text] [Related]
6. Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing-remitting multiple sclerosis.
Lorscheider J; Benkert P; Lienert C; Hänni P; Derfuss T; Kuhle J; Kappos L; Yaldizli Ö
Mult Scler; 2018 May; 24(6):777-785. PubMed ID: 29685071
[TBL] [Abstract][Full Text] [Related]
7. Real-world disability improvement in patients with relapsing-remitting multiple sclerosis treated with natalizumab in the Tysabri Observational Program.
Wiendl H; Spelman T; Butzkueven H; Kappos L; Trojano M; Su R; Campbell N; Ho PR; Licata S
Mult Scler; 2021 Apr; 27(5):719-728. PubMed ID: 32579430
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
Hettle R; Harty G; Wong SL
J Med Econ; 2018 Jul; 21(7):676-686. PubMed ID: 29618273
[TBL] [Abstract][Full Text] [Related]
9. Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.
Bridel C; Leurs CE; van Lierop ZYGJ; van Kempen ZLE; Dekker I; Twaalfhoven HAM; Moraal B; Barkhof F; Uitdehaag BMJ; Killestein J; Teunissen CE
Neurology; 2021 Nov; 97(19):e1898-e1905. PubMed ID: 34504023
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY).
Cohan SL; Moses H; Calkwood J; Tornatore C; LaGanke C; Smoot KE; Meka V; Okwuokenye M; Hotermans C; Mendoza JP; Mann MK; Meltzer LA
Mult Scler Relat Disord; 2018 May; 22():27-34. PubMed ID: 29524759
[TBL] [Abstract][Full Text] [Related]
11. Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years.
Zivadinov R; Hojnacki D; Bergsland N; Kennedy C; Hagemeier J; Melia R; Ramasamy DP; Durfee J; Carl E; Dwyer MG; Weinstock-Guttman B
Eur J Neurol; 2016 Jun; 23(6):1101-9. PubMed ID: 26998905
[TBL] [Abstract][Full Text] [Related]
12. Natalizumab reduces relapse clinical severity and improves relapse recovery in MS.
Lublin FD; Cutter G; Giovannoni G; Pace A; Campbell NR; Belachew S
Mult Scler Relat Disord; 2014 Nov; 3(6):705-11. PubMed ID: 25891549
[TBL] [Abstract][Full Text] [Related]
13. The Use of Natalizumab in Pediatric Patients With Active Relapsing Multiple Sclerosis: A Prospective Study.
Alroughani R; Ahmed SF; Behbehani R; Al-Hashel J
Pediatr Neurol; 2017 May; 70():56-60. PubMed ID: 28389054
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of natalizumab in patients with highly active relapsing remitting multiple sclerosis.
Cobo-Calvo Á; Bau L; Matas E; Romero-Pinel L; Mañé Martínez MA; Majós C; Martínez Yélamos S
Eur Neurol; 2015; 73(3-4):220-229. PubMed ID: 25792347
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.
Perumal J; Fox RJ; Balabanov R; Balcer LJ; Galetta S; Makh S; Santra S; Hotermans C; Lee L
BMC Neurol; 2019 Jun; 19(1):116. PubMed ID: 31176355
[TBL] [Abstract][Full Text] [Related]
16. Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study.
Gajofatto A; Bianchi MR; Deotto L; Benedetti MD
Eur Neurol; 2014; 72(3-4):173-80. PubMed ID: 25226868
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing-remitting multiple sclerosis in Italy.
Furneri G; Santoni L; Ricella C; Prosperini L
BMC Health Serv Res; 2019 Jun; 19(1):436. PubMed ID: 31253138
[TBL] [Abstract][Full Text] [Related]
18. Natalizumab Treatment for Relapsing-Remitting Multiple Sclerosis: The Experience From Saudi Arabia.
Algahtani H; Shirah B; Abobaker H; Alghanaim N; Kamel F
Clin Neuropharmacol; 2018; 41(6):199-201. PubMed ID: 30234558
[TBL] [Abstract][Full Text] [Related]
19. Sustained efficacy of natalizumab in the treatment of relapsing-remitting multiple sclerosis independent of disease activity and disability at baseline: real-life data from a Swiss cohort.
Kallweit U; Jelcic I; Braun N; Fischer H; Zörner B; Schreiner B; Sokolov AA; Martin R; Weller M; Linnebank M
Clin Neuropharmacol; 2012; 35(2):77-80. PubMed ID: 22318192
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.
Putzki N; Yaldizli O; Mäurer M; Cursiefen S; Kuckert S; Klawe C; Maschke M; Tettenborn B; Limmroth V
Eur J Neurol; 2010 Jan; 17(1):31-7. PubMed ID: 19614963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
